Fountain Healthcare Partners
Fountain Healthcare Partners (FHP) is a life-science focused venture capital firm that provides equity capital and sector expertise to entrepreneurs building specialty pharma, biopharmaceuticals, medical device and diagnostics companies. FHP manages multiple funds (three funds reported; €301M AUM), focuses primarily on Europe with US activity, limits the number of active portfolio companies to provide hands-on support, and partners with co-investors to lead or co-lead syndicates.
Fountain Healthcare Partners
New York, New York, United States, North America
Services
Equity investment (risk capital)
Provides venture capital investments across early to later stages, from seed through public offerings; typical per-company deployment is €10M–€15M from its funds.
Active portfolio partnership and operational support
Provides industry expertise, board-level engagement and strategic guidance to portfolio companies to support clinical, regulatory and commercial milestones.
International network and market access
Facilitates cross-border partnerships, US connectivity and exit opportunities through its Dublin and New York offices and industry relationships.
Responsible investment guidance
Integrates responsible investment principles into investment decisions and publishes a Responsible Investment Policy summary.
Equity investment (risk capital)
Provides venture capital investments across early to later stages, from seed through public offerings; typical per-company deployment is €10M–€15M from its funds.
Active portfolio partnership and operational support
Provides industry expertise, board-level engagement and strategic guidance to portfolio companies to support clinical, regulatory and commercial milestones.
International network and market access
Facilitates cross-border partnerships, US connectivity and exit opportunities through its Dublin and New York offices and industry relationships.
Responsible investment guidance
Integrates responsible investment principles into investment decisions and publishes a Responsible Investment Policy summary.
Portfolio
FHP led or participated in multiple financings (including a $70M private placement in 2009) and supported AMR101 through Phase 3 development. Company reported positive MARINE Phase 3 results (Nov 2010) and advanced NDA planning for AMR101 in 2011. FHP partners were active at board level during development milestones.
#Biopharmaceuticals (cardiovascular)
FHP co-led a $17.3M Series C financing in June 2009 (with Mitsui & Co. Venture Partners) to support launch of the Sideguard™ Sidebranch stent in Europe. FHP also participated in the first tranche of a €10.5M Series D investment in November 2010 to support expanded launches, manufacturing capacity and R&D.
#Medical devices (coronary stents)
FHP participated in XyloCor's Series B financing (reported $67.5M) to advance XC001 into Phase 2b (EXACT-2) and other trials. XC001 is a one-time adenoviral gene therapy administered via catheter (Extroducer® system) to promote angiogenesis in refractory angina; the company completed positive Phase 1/2 results and progressed to randomized Phase 2 trials.
#Biopharmaceuticals / Gene therapy (cardiovascular)
FHP is an investor; company progressed PerQseal® and PerQseal® Elite through CE approvals and U.S. IDE/PMA submissions, and secured a €30M strategic investment from Haemonetics in 2023. Vivasure reported positive PATCH pivotal study results and submitted a U.S. PMA for PerQseal Elite.
#Medical devices (vascular closure)
FHP-backed company; NEUROMARK® Next Generation system received FDA 510(k) clearance enabling U.S. commercial validation and expanded product features including real-time feedback for electrode placement.
#Medical devices (ENT; neurostimulation for chronic rhinitis)
FHP participated in an oversubscribed €10M financing to accelerate commercialisation; Lenire received FDA De Novo authorization (March 2023) and has published pivotal clinical trial results and real-world evidence supporting its use.
#Medical devices / Neurostimulation (tinnitus)
FHP led or participated in multiple financings (including a $70M private placement in 2009) and supported AMR101 through Phase 3 development. Company reported positive MARINE Phase 3 results (Nov 2010) and advanced NDA planning for AMR101 in 2011. FHP partners were active at board level during development milestones.
#Biopharmaceuticals (cardiovascular)
FHP co-led a $17.3M Series C financing in June 2009 (with Mitsui & Co. Venture Partners) to support launch of the Sideguard™ Sidebranch stent in Europe. FHP also participated in the first tranche of a €10.5M Series D investment in November 2010 to support expanded launches, manufacturing capacity and R&D.
#Medical devices (coronary stents)
FHP participated in XyloCor's Series B financing (reported $67.5M) to advance XC001 into Phase 2b (EXACT-2) and other trials. XC001 is a one-time adenoviral gene therapy administered via catheter (Extroducer® system) to promote angiogenesis in refractory angina; the company completed positive Phase 1/2 results and progressed to randomized Phase 2 trials.
#Biopharmaceuticals / Gene therapy (cardiovascular)
FHP is an investor; company progressed PerQseal® and PerQseal® Elite through CE approvals and U.S. IDE/PMA submissions, and secured a €30M strategic investment from Haemonetics in 2023. Vivasure reported positive PATCH pivotal study results and submitted a U.S. PMA for PerQseal Elite.
#Medical devices (vascular closure)
FHP-backed company; NEUROMARK® Next Generation system received FDA 510(k) clearance enabling U.S. commercial validation and expanded product features including real-time feedback for electrode placement.
#Medical devices (ENT; neurostimulation for chronic rhinitis)
FHP participated in an oversubscribed €10M financing to accelerate commercialisation; Lenire received FDA De Novo authorization (March 2023) and has published pivotal clinical trial results and real-world evidence supporting its use.
#Medical devices / Neurostimulation (tinnitus)